Miguel Rodriguez, MD
Pulmonary Disease · Springfield, MANPI 1952370249
Payments from drug & device makers
Across 107 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$952
- Boehringer Ingelheim$174
- AstraZeneca$131
- Tanabe Pharma America, Inc.$100
- Novartis$91
- Actelion Pharmaceuticals US, Inc.$81
- plus $442 from 11 others
What the payments were for
- Food & beverage$1,88596%
- Education$874%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $952 |
| Boehringer Ingelheim | 7 | $174 |
| AstraZeneca | 6 | $131 |
| Tanabe Pharma America, Inc. | 1 | $100 |
| Novartis | 6 | $91 |
| Actelion Pharmaceuticals US, Inc. | 5 | $81 |
| Resmed Corp | 1 | $66 |
| Genentech USA, Inc. | 3 | $63 |
| Insmed, Inc. | 3 | $57 |
| Amgen | 2 | $55 |
| Grifols USA, LLC | 2 | $51 |
| Verona Pharma, Inc. | 2 | $45 |
| Philips North America LLC | 1 | $25 |
| Sanofi | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$225
- Radicava$100
How this compares
$1,972 in reported general payments places this provider in the 65th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,110 | $809,114 |
| Dupixent PenDupilumab | 88 | $326,030 |
| Dupixent SyringeDupilumab | 69 | $252,646 |
| OfevNintedanib Esylate | 17 | $220,338 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $143,888 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 213 | $133,847 |
| Spiriva RespimatTiotropium Bromide | 169 | $125,689 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 184 | $121,921 |
| Breo ElliptaFluticasone/Vilanterol | 253 | $121,224 |
| FasenraBenralizumab | 21 | $120,118 |
| NucalaMepolizumab | 25 | $96,492 |
| Advair HfaFluticasone Propion/Salmeterol | 213 | $82,675 |
| Incruse ElliptaUmeclidinium Bromide | 151 | $60,959 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 197 | $43,752 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 73 | $37,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $952 | $1,235,9451,820 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $174 | $402,212288 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Bevespi Aerosphere, Daliresp | $131 | $300,818375 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Springfield
- Mary Jo FarmerSpringfield$131K
- Victor Pinto-PlataSpringfield$59K
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Ehab BillatosWinchester$2.7M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Curtis MelloNorth Dartmouth$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.